The Cooper Companies, Inc. with ticker code (COO) now have 12 analysts in total covering the stock. The consensus rating is pointing to ‘Buy’. The range between the high target price and low target price is between 560 and 280 suggesting an average Analsyt target price of $372.08. Now with the previous closing price of $344.51 this now indicates there is a potential upside of 8.0%. The 50 day MA is $341.89 and the 200 day MA is $313.87. The market cap for the company is $17,196m. Find out more information at: https://www.coopercos.com
The potential market cap would be $18,572m based on the market consensus.
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia Pacific. The CooperSurgical segment focuses on family and women’s health care, which provides medical devices, fertility, genomics, diagnostics, and contraception to health care professionals and patients worldwide. It offers surgical and office products, including PARAGARD, uterine manipulators, retractors, closure products, point of care products, LEEP products, endosee, and illuminate and fetal pillows; fertility products and services, such as fertility consumables and equipment, and embryo options and preimplantation genetic testing. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
The company has a dividend yield of 0.02% with the ex dividend date set at 20-1-2023 (DMY).
Other points of data to note are a P/E ratio of 46.11, revenue per share of 68.55 and a 3% return on assets.
